- Home
- TRML vs FISI Comparison
TRML vs FISI Comparison
Compare TRML & FISI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRML
- FISI
- Stock Information
- Founded
- TRML 2021
- FISI 1817
- Country
- TRML United States
- FISI United States
- Employees
- TRML N/A
- FISI N/A
- Industry
- TRML Biotechnology: Pharmaceutical Preparations
- FISI Major Banks
- Sector
- TRML Health Care
- FISI Finance
- Exchange
- TRML Nasdaq
- FISI Nasdaq
- Market Cap
- TRML 419.1M
- FISI 416.4M
- IPO Year
- TRML N/A
- FISI 1999
- Fundamental
- Price
- TRML $23.01
- FISI $27.90
- Analyst Decision
- TRML Strong Buy
- FISI Hold
- Analyst Count
- TRML 3
- FISI 2
- Target Price
- TRML $65.00
- FISI $22.00
- AVG Volume (30 Days)
- TRML 187.7K
- FISI 43.5K
- Earning Date
- TRML 11-07-2024
- FISI 10-24-2024
- Dividend Yield
- TRML N/A
- FISI 4.30%
- EPS Growth
- TRML N/A
- FISI N/A
- EPS
- TRML N/A
- FISI 3.17
- Revenue
- TRML N/A
- FISI $216,605,000.00
- Revenue This Year
- TRML N/A
- FISI N/A
- Revenue Next Year
- TRML N/A
- FISI $6.94
- P/E Ratio
- TRML N/A
- FISI $8.80
- Revenue Growth
- TRML N/A
- FISI 9.25
- 52 Week Low
- TRML $12.12
- FISI $16.29
- 52 Week High
- TRML $48.31
- FISI $28.14
- Technical
- Relative Strength Index (RSI)
- TRML 37.25
- FISI 62.80
- Support Level
- TRML $25.58
- FISI $26.00
- Resistance Level
- TRML $27.51
- FISI $28.12
- Average True Range (ATR)
- TRML 1.81
- FISI 0.74
- MACD
- TRML -0.61
- FISI 0.09
- Stochastic Oscillator
- TRML 10.76
- FISI 93.85
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
About FISI Financial Institutions Inc.
Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.